bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: O S A J J M A M F J
2013: D N O

 
  Other news for:
Lymphoma
 Resources from HONselect
FDA Expands Use of Imbruvica for Form of Leukemia
People with CLL and a specific genetic anomaly can now get the therapy

By Scott Roberts

MONDAY, July 28, 2014 (HealthDay News) -- Approved use for Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have a deletion in chromosome 17, the U.S. Food and Drug Administration said Monday in a news release.

People with the 17p deletion are prone to a poor response to standard therapies for CLL, the agency noted.

CLL, a form of non-Hodgkin lymphoma, generally gets worse over time and leads to a gradual increase in white blood cells called B lymphocytes. Almost 16,000 Americans will be diagnosed with CLL and 4,600 will die from it this year, the FDA said, citing projections from the U.S. National Cancer Institute.

The expanded approval followed a clinical study of 391 people, 127 of whom had the 17p deletion. The trial was stopped early after participants treated with Imbruvica showed a 78 percent reduction in risk of disease progression or death, the FDA said.

The most common side effects reported were a decrease in infection-fighting white blood cells, diarrhea, anemia, fatigue, muscle and bone pain, upper respiratory tract infection, rash, nausea and fever.

Imbruvica was approved in November 2013 to treat mantle cell lymphoma among people who had been given at least one prior therapy.

The drug is co-marketed by Sunnyvale, Calif.-based Pharmacyclics and Horsham, Penn.-based Janssen Biotech.

More information

The FDA has more about this approval.

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=690194

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Leukemia
Lymphoma
Cells
Blood Cells
Blood
Leukocytes
Infection
Disease Progression
Leukemia, Lymphocytic
Fever
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact